Related Experiment Videos
Efficacy of interventions designed to inhibit the progression of coronary atherosclerosis
1Department of Preventive Medicine, University of Southern California, Los Angeles 90033, USA.
Insights
Antiatherosclerosis interventions effectively inhibit coronary artery disease (CAD) progression, with benefits varying by lesion severity. Further research is needed for diabetic populations and to explore novel risk factors and noninvasive measures.
Area of Science:
- Cardiology
- Medical Interventions
- Clinical Trials
Background:
- Coronary artery disease (CAD) remains a leading cause of mortality.
- Understanding interventions that inhibit CAD progression is crucial.
- Serial coronary angiography has emerged as a validated surrogate endpoint.
Purpose of the Study:
- To review randomized coronary angiographic trials and assess antiatherosclerosis interventions.
- To demonstrate the efficacy of these interventions in inhibiting CAD progression.
- To explore differential treatment benefits based on lesion severity and identify risk factors.
Main Methods:
- Review of published randomized coronary angiographic trials.
- Estimation of treatment effect sizes from trial data.
- Ancillary analyses to identify CAD progression risk factors.
Main Results:
- Antiatherosclerosis interventions are effective in inhibiting CAD progression.
- Treatment benefits vary depending on initial lesion severity.
- Triglyceride-rich lipoproteins are implicated as significant risk factors for CAD progression.
Conclusions:
- Antiatherosclerosis interventions demonstrate efficacy in managing CAD.
- Initial lesion severity influences treatment benefit.
- Further investigation into diabetic populations and novel risk factors is warranted.
Abstract:
This paper reviews the design and results of published randomized coronary angiographic trials and estimates treatment effect sizes for these trials to clearly demonstrate that antiatherosclerosis interventions are effective in inhibiting the progression of coronary artery disease (CAD). Furthermore, these interventions show differential treatment benefit on particular lesion populations defined by initial lesion severity. The efficacy of such interventions have been virtually unstudied in diabetic populations. Ancillary analyses of these trials implicate certain risk factors for the continued progression of CAD assessed by coronary angiography; although standard lipids such as total cholesterol and LDL-cholesterol are important risk factors, recent evidence suggests that triglycride-rich lipoproteins are also important contributors to progression of CAD, both in treated and untreated trial subjects. Recent reports demonstrating an association between progression of coronary disease assessed by coronary angiography and the risk of clinical events provide critical validation for the use of serial coronary angiography as a surrogate endpoint measure in controlled clinical trials. Finally, the advent of noninvasive ultrasonographic measures of carotid intima-media thickness may provide an important avenue for future testing of antiatherosclerosis interventions.